Hot Life Science Investor Mandate 3: Corporate Venture Fund Seeks Therapeutics with Companion Diagnostics – January 29, 2013

29 Jan

A corporate venture fund with offices worldwide – one of the oldest in the world – is interested in the biotech therapeutics and diagnostics space. The fund has invested more than $500 million in the life science space since its founding, has an evergreen structure, and deploys capital on an opportunistic basis, pulling money directly from their main fund as investment opportunities are uncovered. They typically invest in up to 10 firms per year, usually allocating $1-10 million per company.

The firm is most interested in novel therapeutics, and would be especially interested in therapeutics firms that are developing a therapeutic with a companion diagnostic. They are also very interested in small molecule-based therapeutics, as well as companies producing medical devices. The firm has a global investment mandate.

In terms of their interest in therapeutics, the firm is looking for companies whose products are in the preclinical, Phase I, or Phase IIb (proof-of-concept) stage of development, and for medical device companies, the firm will look at firms that have a product in development or companies that have a prototype of their product.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: